Pretty much every page of the new IQVIA “Global Trends in R&D 2024” report is worth deep consideration. It is the definitive atlas of how and where biopharma is investing

I could try to summarize it, but you’re probably better off just clicking over the Adam Fein’s latest post at Drug Channels today. Adam take a deep dive into the

After a chill week, we’re back to drinking from the firehose. One of the larger, if not sufficiently heralded, wins for the patient advocacy community last year was the effort

It’s the Friday before a long weekend, so it’s all Quick Turns into the weekend. See you Tuesday. CNN has a new piece on 2024 price hikes. I give them

It’s been a slow week, so it’s probably useful for me to pause for a moment and think about what’s coming. Here’s a short list of the milestones that I’m

Every year, I think to myself: is this the year where public pressure finally gets so great that health plans can no longer get away with copay accumulators? Of all

CORRECTION: Last week, I flagged a study that looked at prices for generic drugs at a number of “direct to consumer” pharmacies. I noted that the researchers compared the prices

One of the great freedoms of the newsletter format is that they can be as long or as short as they need to be. So while I’m going to be

I guess I’m supposed to write about the Senate HELP hearing yesterday. I’ve certainly wasted a bunch of pixels in the runup. It would be weird if I ignored it

It’s a short newsletter today because my attention will be on Washington today. I plan to watch as much of the Senate hearing as I can stand. There’s a lot